Direct oral anticoagulants (DOACs)—dabigatran, rivaroxaban, apixaban and edoxaban—are changing the landscape of clinical practice for patients requiring short and long-term anticoagulation. We report a patient with no history of kidney disease developing acute interstitial nephritis (AIN) after starting a DOAC, apixaban. To date, this is the first biopsy proven case of apixaban-induced AIN.
NephSIM is a free, mobile-optimized, nephrology teaching tool that includes case-based learning, infographics, tutorials & more!
Submit your picks! | NephMadness 2024 | #NephMadness Selection Committee Member: Mirjam Christ-Crain @ChristCrain Mirjam Christ-Crain is Full Professor and Deputy Chief of Endocrinology at…
Membranous nephropathy (MN) is a leading cause of kidney failure worldwide and frequently recurs after transplant. Available data originated from small retrospective cohort studies or…
The guideline is a focused update of the ANCA Vasculitis chapter of the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The…
The guideline is a focused update of the ANCA Vasculitis chapter of the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The…
The guideline is a focused update of the ANCA Vasculitis chapter of the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The…
The guideline is a focused update of the ANCA Vasculitis chapter of the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The…
The transplant workforce crisis is well-described and will likely worsen in upcoming years. In 2021, over 25,000 kidney transplants were performed in the United States…
Submit your picks! | NephMadness 2022 | #NephMadness | #AnimalHouse Selection Committee Member: Kelly Hyndman @DrKeeksPhD Kelly Hyndman is an Assistant Professor of Medicine in…
